Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12763MR)

This product GTTS-WQ12763MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12763MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11083MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ5031MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ6752MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ11207MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ4227MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ7031MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ6284MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ5328MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW